Theoretical study of omeprazole behavior: Racemization barrier and decomposition reaction

被引:10
作者
Bruni, Aline Thais [1 ]
Castro Ferreira, Marcia Miguel [2 ]
机构
[1] Univ Estadual Paulista, Dept Fis, IBILCE, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil
[2] Univ Estadual Campinas, Inst Quimiometria Teor & Aplicada, BR-13083970 Campinas, SP, Brazil
关键词
omeprazole; racemization; quantum chemistry; conformational analysis; PCA;
D O I
10.1002/qua.21597
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
omeprazole is a substituted benzimidazole which suppresses gastric-acid secretion by means of H+, K+-ATPase inhibition. It is an optically active drug with the sulfur of the sulfoxide being the chiral center. This pro-drug can be easily converted into its respective sulfenamide at low pH. In this work, omeprazole has been studied in relation to racemization barrier and decomposition reaction. Quantum chemistry coupled to PCA chemometric method were used to find all minimum energy structures. Conformational analysis and calculation of racemization barriers were carried out by PM3 semiempirical method (Gaussian 98). The average racemization energy barrier for all minimum energy structures (43.56 kcal mol(-1)) can be related to the velocity constant in Eyring's equation. The enormous half-life time at 100 degrees C (9.04 x 10(4) years) indicates that the process cannot be observed in human time scale. On the other hand, the difference of free energy change (Delta(Delta G) = -266.78 kcal mol(-1)) for the decomposition reaction shows that the process is favorable to the sulfenamide formation. The highly negative Delta(Delta G) obtained for the decomposition reaction shows that this process is extremely exothermic. This result explains why omeprazole decomposes and does not racemize. (C) 2008 Wiley Periodicals, Inc.
引用
收藏
页码:1097 / 1106
页数:10
相关论文
共 44 条
[1]  
Äbelö A, 2000, DRUG METAB DISPOS, V28, P966
[2]   Theoretical evidence of persistent chirality in D3 homoleptic hexacoordinate complexes with monodentate ligands [J].
Alemany, P ;
Alvarez, S ;
Avnir, D .
CHEMISTRY-A EUROPEAN JOURNAL, 2003, 9 (09) :1952-1957
[3]  
Allenmark S, 1997, CHIRALITY, V9, P638, DOI 10.1002/(SICI)1520-636X(1997)9:5/6<638::AID-CHIR35>3.3.CO
[4]  
2-Q
[5]   Pharmacokinetics, metabolism and interactions of acid pump inhibitors - Focus on omeprazole, lansoprazole and pantoprazole [J].
Andersson, T .
CLINICAL PHARMACOKINETICS, 1996, 31 (01) :9-28
[6]   Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole [J].
Andersson, T ;
Hassan-Alin, M ;
Hasselgren, G ;
Röhss, K ;
Weidolf, L .
CLINICAL PHARMACOKINETICS, 2001, 40 (06) :411-426
[7]  
ANDERSSON T, 2000, GASTROENTEROLOGY S2, V118, P1210
[8]  
Atkins P. W., 1990, PHYS CHEM
[9]   Computer simulation of liquid tetramethylurea and its aqueous solution [J].
Belletato, P ;
Freitas, LCG ;
Areâs, EPG ;
Santos, PS .
PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 1999, 1 (20) :4769-4776
[10]   Systematic search in conformational analysis [J].
Beusen, DD ;
Shands, EFB ;
Karasek, SF ;
Marshall, GR ;
Dammkoehler, RA .
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM, 1996, 370 (2-3) :157-171